Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 13 | 2025 | 147 | 4.960 |
Why?
|
| Cardiovascular Diseases | 12 | 2026 | 861 | 3.730 |
Why?
|
| Diabetic Nephropathies | 7 | 2026 | 37 | 3.380 |
Why?
|
| Albuminuria | 4 | 2025 | 28 | 2.620 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2026 | 731 | 2.280 |
Why?
|
| Mortality | 3 | 2024 | 159 | 2.210 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 3 | 2024 | 6 | 1.960 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 4 | 2026 | 14 | 1.860 |
Why?
|
| Kidney Failure, Chronic | 4 | 2025 | 196 | 1.840 |
Why?
|
| Naphthyridines | 2 | 2026 | 7 | 1.630 |
Why?
|
| Nutrition Surveys | 5 | 2026 | 149 | 1.600 |
Why?
|
| Hyponatremia | 3 | 2022 | 11 | 1.570 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 205 | 1.560 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 219 | 1.540 |
Why?
|
| Metabolic Syndrome | 2 | 2025 | 146 | 1.530 |
Why?
|
| Kidney | 7 | 2025 | 450 | 1.500 |
Why?
|
| Kidney Diseases | 4 | 2025 | 177 | 1.310 |
Why?
|
| Glomerular Filtration Rate | 6 | 2024 | 120 | 1.310 |
Why?
|
| Biomarkers | 8 | 2026 | 1476 | 1.280 |
Why?
|
| Betacoronavirus | 3 | 2020 | 181 | 1.240 |
Why?
|
| Diabetes Mellitus | 4 | 2026 | 555 | 1.240 |
Why?
|
| Acute Kidney Injury | 4 | 2024 | 142 | 1.130 |
Why?
|
| Humans | 57 | 2026 | 64954 | 1.070 |
Why?
|
| Pandemics | 4 | 2020 | 672 | 1.060 |
Why?
|
| Amyloidosis | 2 | 2024 | 68 | 0.990 |
Why?
|
| Prediabetic State | 1 | 2026 | 54 | 0.930 |
Why?
|
| Risk Factors | 13 | 2026 | 5408 | 0.910 |
Why?
|
| Metabolic Diseases | 1 | 2025 | 59 | 0.850 |
Why?
|
| Adiposity | 1 | 2024 | 83 | 0.830 |
Why?
|
| Creatinine | 5 | 2024 | 135 | 0.790 |
Why?
|
| Neoplasms | 3 | 2023 | 1365 | 0.770 |
Why?
|
| Water Intoxication | 1 | 2022 | 1 | 0.760 |
Why?
|
| Polydipsia, Psychogenic | 1 | 2022 | 1 | 0.760 |
Why?
|
| Resuscitation | 1 | 2023 | 67 | 0.750 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 150 | 0.730 |
Why?
|
| Adult | 19 | 2026 | 17313 | 0.700 |
Why?
|
| Disease Progression | 8 | 2026 | 1214 | 0.680 |
Why?
|
| Kidney Transplantation | 1 | 2024 | 324 | 0.680 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 182 | 0.680 |
Why?
|
| Coronavirus | 1 | 2020 | 14 | 0.660 |
Why?
|
| ADAM17 Protein | 1 | 2020 | 8 | 0.650 |
Why?
|
| Renal Dialysis | 4 | 2019 | 191 | 0.640 |
Why?
|
| Lactic Acid | 1 | 2020 | 75 | 0.630 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 63 | 0.620 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 140 | 0.600 |
Why?
|
| Incidence | 6 | 2025 | 1415 | 0.600 |
Why?
|
| Renal Insufficiency | 2 | 2024 | 67 | 0.570 |
Why?
|
| Aged | 20 | 2026 | 14924 | 0.570 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 178 | 0.570 |
Why?
|
| Heart Failure | 3 | 2023 | 948 | 0.560 |
Why?
|
| Middle Aged | 18 | 2026 | 18208 | 0.550 |
Why?
|
| Hypertension | 5 | 2025 | 610 | 0.550 |
Why?
|
| Female | 25 | 2026 | 33927 | 0.520 |
Why?
|
| Hyperoxaluria | 3 | 2024 | 10 | 0.510 |
Why?
|
| Male | 23 | 2026 | 30953 | 0.490 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2020 | 45 | 0.480 |
Why?
|
| Risk Assessment | 5 | 2025 | 2094 | 0.470 |
Why?
|
| Prospective Studies | 8 | 2024 | 3305 | 0.470 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 15 | 0.440 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2015 | 44 | 0.430 |
Why?
|
| Patient Preference | 1 | 2015 | 86 | 0.420 |
Why?
|
| Prognosis | 5 | 2025 | 1775 | 0.410 |
Why?
|
| Renin-Angiotensin System | 2 | 2026 | 22 | 0.400 |
Why?
|
| Bleaching Agents | 1 | 2013 | 6 | 0.390 |
Why?
|
| Sodium Hypochlorite | 1 | 2013 | 12 | 0.390 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 385 | 0.390 |
Why?
|
| Diuretics | 2 | 2025 | 58 | 0.380 |
Why?
|
| United States | 5 | 2026 | 8083 | 0.370 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 34 | 0.370 |
Why?
|
| Receptors, Mineralocorticoid | 2 | 2022 | 4 | 0.360 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 256 | 0.360 |
Why?
|
| Patient Safety | 1 | 2015 | 258 | 0.360 |
Why?
|
| Republic of Korea | 2 | 2024 | 207 | 0.360 |
Why?
|
| Cause of Death | 2 | 2024 | 221 | 0.350 |
Why?
|
| Puerperal Disorders | 1 | 2011 | 15 | 0.350 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2011 | 12 | 0.350 |
Why?
|
| Cohort Studies | 5 | 2025 | 2614 | 0.330 |
Why?
|
| Mother-Child Relations | 1 | 2011 | 46 | 0.330 |
Why?
|
| Machine Learning | 2 | 2024 | 192 | 0.320 |
Why?
|
| Signal Transduction | 1 | 2020 | 3143 | 0.310 |
Why?
|
| Young Adult | 3 | 2026 | 4793 | 0.290 |
Why?
|
| Cross-Sectional Studies | 4 | 2026 | 2702 | 0.290 |
Why?
|
| Prevalence | 2 | 2026 | 1439 | 0.280 |
Why?
|
| Pneumonia | 1 | 2011 | 291 | 0.270 |
Why?
|
| Albumins | 2 | 2024 | 43 | 0.250 |
Why?
|
| Recovery of Function | 3 | 2024 | 291 | 0.250 |
Why?
|
| Time Factors | 3 | 2025 | 3758 | 0.240 |
Why?
|
| Communication | 1 | 2011 | 595 | 0.240 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2024 | 76 | 0.240 |
Why?
|
| Aldosterone | 2 | 2022 | 18 | 0.230 |
Why?
|
| Potassium | 2 | 2022 | 97 | 0.230 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2024 | 16 | 0.220 |
Why?
|
| Pancreas | 1 | 2025 | 154 | 0.220 |
Why?
|
| Nephrologists | 1 | 2024 | 7 | 0.220 |
Why?
|
| Waist Circumference | 1 | 2024 | 47 | 0.220 |
Why?
|
| Osteopontin | 1 | 2024 | 21 | 0.220 |
Why?
|
| Proteomics | 2 | 2024 | 292 | 0.210 |
Why?
|
| Stroke | 2 | 2024 | 1208 | 0.210 |
Why?
|
| Foreign-Body Migration | 1 | 2024 | 24 | 0.210 |
Why?
|
| Angiotensins | 2 | 2020 | 3 | 0.200 |
Why?
|
| Device Removal | 1 | 2024 | 64 | 0.200 |
Why?
|
| Kidney Glomerulus | 1 | 2023 | 23 | 0.200 |
Why?
|
| Aphasia | 1 | 2024 | 47 | 0.200 |
Why?
|
| Cystatin C | 1 | 2023 | 9 | 0.200 |
Why?
|
| Atrial Appendage | 1 | 2024 | 41 | 0.190 |
Why?
|
| Fluid Therapy | 1 | 2023 | 46 | 0.190 |
Why?
|
| Apolipoprotein L1 | 1 | 2022 | 6 | 0.190 |
Why?
|
| Neovascularization, Pathologic | 1 | 2023 | 140 | 0.190 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 6 | 0.180 |
Why?
|
| Canagliflozin | 1 | 2022 | 6 | 0.180 |
Why?
|
| India | 2 | 2024 | 164 | 0.180 |
Why?
|
| Body Mass Index | 2 | 2024 | 890 | 0.180 |
Why?
|
| Models, Immunological | 1 | 2022 | 85 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2482 | 0.170 |
Why?
|
| Chronic Disease | 1 | 2024 | 741 | 0.170 |
Why?
|
| Patient Selection | 1 | 2024 | 483 | 0.170 |
Why?
|
| Hypophosphatemia, Familial | 1 | 2020 | 4 | 0.170 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIa | 1 | 2020 | 4 | 0.160 |
Why?
|
| Nephrolithiasis | 1 | 2020 | 8 | 0.160 |
Why?
|
| Ascites | 1 | 2020 | 22 | 0.160 |
Why?
|
| Glucosides | 1 | 2020 | 15 | 0.160 |
Why?
|
| Ions | 1 | 2020 | 54 | 0.160 |
Why?
|
| Osmolar Concentration | 1 | 2020 | 90 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 735 | 0.160 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 67 | 0.160 |
Why?
|
| Vasodilation | 1 | 2020 | 36 | 0.160 |
Why?
|
| Atherosclerosis | 1 | 2022 | 160 | 0.160 |
Why?
|
| Lung Injury | 1 | 2020 | 36 | 0.160 |
Why?
|
| Drainage | 1 | 2020 | 152 | 0.150 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 61 | 0.150 |
Why?
|
| Drug Discovery | 1 | 2020 | 95 | 0.150 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2019 | 33 | 0.150 |
Why?
|
| Immunity | 1 | 2020 | 107 | 0.150 |
Why?
|
| Virus Internalization | 1 | 2020 | 91 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 168 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 739 | 0.140 |
Why?
|
| Calcium | 1 | 2022 | 581 | 0.140 |
Why?
|
| Maternal Mortality | 1 | 2018 | 16 | 0.140 |
Why?
|
| Infant Mortality | 1 | 2018 | 20 | 0.130 |
Why?
|
| Pregnancy | 2 | 2018 | 2372 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2024 | 5776 | 0.130 |
Why?
|
| Oxalates | 3 | 2024 | 19 | 0.130 |
Why?
|
| Gene Expression | 1 | 2020 | 852 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 801 | 0.130 |
Why?
|
| White Matter | 1 | 2018 | 125 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5601 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2018 | 373 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 197 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 918 | 0.120 |
Why?
|
| Comorbidity | 2 | 2025 | 1113 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 871 | 0.110 |
Why?
|
| United Kingdom | 2 | 2025 | 85 | 0.110 |
Why?
|
| Algorithms | 1 | 2020 | 1044 | 0.110 |
Why?
|
| Vascular Grafting | 1 | 2015 | 37 | 0.110 |
Why?
|
| Coronary Disease | 2 | 2012 | 246 | 0.100 |
Why?
|
| Brain | 2 | 2024 | 1601 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 350 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2015 | 129 | 0.100 |
Why?
|
| Infant, Newborn | 1 | 2018 | 1416 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 159 | 0.100 |
Why?
|
| Patient Participation | 1 | 2015 | 231 | 0.090 |
Why?
|
| Infant | 1 | 2018 | 1683 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1557 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 240 | 0.090 |
Why?
|
| Suicide, Attempted | 1 | 2013 | 111 | 0.090 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2011 | 8 | 0.090 |
Why?
|
| Neurologic Examination | 1 | 2011 | 53 | 0.090 |
Why?
|
| Obesity | 1 | 2019 | 1266 | 0.080 |
Why?
|
| Alzheimer Disease | 1 | 2018 | 765 | 0.080 |
Why?
|
| Child | 1 | 2020 | 4606 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 214 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 1655 | 0.080 |
Why?
|
| Patients | 1 | 2011 | 114 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2012 | 317 | 0.080 |
Why?
|
| Health Behavior | 1 | 2011 | 483 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 706 | 0.060 |
Why?
|
| Health Promotion | 1 | 2011 | 512 | 0.060 |
Why?
|
| Mice | 1 | 2020 | 11088 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 767 | 0.060 |
Why?
|
| Organ Size | 1 | 2025 | 173 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2020 | 6842 | 0.060 |
Why?
|
| Biological Specimen Banks | 1 | 2025 | 23 | 0.060 |
Why?
|
| Tenascin | 1 | 2024 | 4 | 0.050 |
Why?
|
| Kidney Tubules | 1 | 2024 | 23 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2024 | 84 | 0.050 |
Why?
|
| Curcuma | 1 | 2024 | 2 | 0.050 |
Why?
|
| Aortography | 1 | 2024 | 58 | 0.050 |
Why?
|
| Aorta, Abdominal | 1 | 2024 | 56 | 0.050 |
Why?
|
| Embolism | 1 | 2024 | 41 | 0.050 |
Why?
|
| Urinalysis | 1 | 2023 | 37 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 115 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2024 | 219 | 0.050 |
Why?
|
| Proteinuria | 1 | 2023 | 41 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2025 | 2240 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 140 | 0.050 |
Why?
|
| Urea | 1 | 2022 | 41 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 59 | 0.050 |
Why?
|
| Renal Elimination | 1 | 2022 | 3 | 0.050 |
Why?
|
| Adolescent | 1 | 2013 | 6293 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2024 | 292 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 21292 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 454 | 0.040 |
Why?
|
| Thrombosis | 1 | 2024 | 206 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2024 | 235 | 0.040 |
Why?
|
| Phosphorus | 1 | 2020 | 16 | 0.040 |
Why?
|
| Renin | 1 | 2020 | 10 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 576 | 0.040 |
Why?
|
| Genotype | 1 | 2022 | 673 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 38 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 257 | 0.040 |
Why?
|
| Transcriptome | 1 | 2023 | 398 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 273 | 0.040 |
Why?
|
| Sex Factors | 1 | 2022 | 991 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 460 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 483 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 151 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2018 | 95 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 1231 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 988 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 951 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 410 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1138 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2021 | 819 | 0.030 |
Why?
|
| Inflammation | 1 | 2019 | 1186 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 261 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 525 | 0.020 |
Why?
|
| Smoking | 1 | 2011 | 861 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 961 | 0.010 |
Why?
|